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Abstract
Introduction: Type 2 diabetes mellitus, a metabolic disease with increasing incidence, is one of the most important cardiovascular risk
factors. Insulin resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Metformin and the
thiazolidinediones, pioglitazone and rosiglitazone, are insulin-sensitizing agents available for treatment of type 2 diabetes. Large clinical
trials have demonstrated the effectiveness of both metformin and pioglitazone in reducing cardiovascular morbidity and mortality. The
fixed-dose combination of metformin and pioglitazone appears to be a good option for treating diabetes in insulin-resistant patients.
Aims: The purpose of this article is to review the place in therapy of a fixed-dose combination of pioglitazone and metformin in the
management of patients with type 2 diabetes.
Evidence review: The current evidence suggests that combined therapy may help to achieve the recommended goals in the
management of diabetes. A fixed-dose formulation of pioglitazone and metformin may provide advantages in terms of glycemic control
and other cardiovascular risk factors frequently associated with diabetes.
Place in therapy: The current evidence shows that a fixed-dose formulation of pioglitazone and metformin offers an effective option for
the management of patients with type 2 diabetes when monotherapy fails in the achievement of the recommended standards of care.
Core Evidence. 2007;2(3):189–198
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Core evidence place in therapy summary for pioglitazone/metformin fixed-dose combination in
type 2 diabetes mellitus
Outcome measure Evidence Implications
Improvement in glycemic control and insulin sensitivity Clear As effective as pioglitazone/sulfonylureas and metformin/sulfonylureas on glycemic
control. Comparable to rosiglitazone/metformin on insulin sensitivity, and more
effective than metformin/sulfonylureas
Improvement in lipid abnormalities Substantial More effective than rosiglitazone/sulfonylureas combination
Improvement in other cardiovascular risk factors Substantial Improves nonconventional cardiovascular risk factors
Hypertension Moderate More long-term clinical trials adjusted for use of antihypertensive treatment
are required
Patient convenience Moderate Adverse effects comparable to those with other combinations
Cost effectiveness Unclear More long-term studies requiredScope, aims, and objectives
Pioglitazone/metformin fixed-dose formulation combines two
insulin sensitizers: metformin, a biguanide, and pioglitazone, a
thiazolidinedione (TZD). This combination has been developed
for the management of patients with type 2 diabetes mellitus
who are intolerant or not adequately controlled with metformin
monotherapy, and has been approved in the US and EU.
Combination treatment may be more suitable for some diabetic
patients who are frequently treated with multiple drugs.
Metformin and pioglitazone are well-known insulin-sensitizing
agents that act through different mechanisms. The mechanism
of action of both metformin and pioglitazone is still not
completely understood. However, the large spectrum of
effects of pioglitazone makes the combination of
metformin and pioglitazone a promising treatment option
not only for optimizing management of glycemic control
but also for prevention of the cardiovascular complications
of diabetes. Side effects induced by combination treatment
are also addressed in the article. The largest part of
literature available for the combination treatment is from
studies of pioglitazone and metformin given together as
separate drugs, since few data are available with fixed-dose
combination treatment.
The purpose of this article is to review the place in therapy of a
fixed-dose combination of pioglitazone and metformin in the
management of patients with type 2 diabetes.
Methods
The English language medical literature was reviewed for
appropriate articles on pioglitazone/metformin combination
treatment for the treatment of type 2 diabetes. The following
databases were searched between May and June 2007 using
the search term “pioglitazone metformin.”
• PubMed, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi
• EMBASE, http://www.datastarweb.com
• Database of Abstracts of Reviews of Effects (DARE), National
Health Service (NHS) Economic Evaluation Database
(NHSEED), Health Technology Assessment (HTA),
http://www.york.ac.uk/inst/crd/crddatabases.htm. All three
databases were searched together. All fields searched
• Cochrane Database of Systematic Reviews (CDSR),
http://www.cochrane.org
• BIOSIS, http://www.datastarweb.com
• National Institute for Health and Clinical Evidence (NICE),
http://www.nice.org.uk
No date limitations were placed on the search. Numerous
guidelines related to type 2 diabetes management were
examined, although only American Diabetes Association (ADA)
guidelines were considered (ADA 2007).
The level of evidence identified from the literature search is
described in Table 1.
Disease overview
Increasing numbers of patients with type 2 diabetes are
identified every year all over the world; recent data suggest that
around 246 million people are affected by type 2 diabetes, and
this number is expected to be around 380 million by 2025 (IDF
2006). The associated annual mortality rate has been estimated
to be around 5.5% of all patients (White et al. 2003). The
prevalence of type 2 diabetes is largely variable with ethnicity
and age. Direct medical costs for diabetes (i.e. the total costs
of medical care) are increased when diabetes is poorly
controlled and diabetes complications are present (Gilmer et
al. 2007).
The underlying mechanism that leads to diabetes is recognized
as insulin resistance, which appears to be involved in a number
of other cardiovascular disorders such as hypertension (Rosak
2002). Frequently, type 2 diabetes is associated with higher
cardiovascular risk (Mann 2002). The role of type 2 diabetes in
the development of atherosclerotic disease is well established
(National Service Framework for Diabetes 2001). Recently, a
cluster of cardiovascular disorders have been unified under the
definition of “metabolic syndrome,” which is characterized by a
high cardiovascular risk (Haffner 2007).
Types 2 diabetes is frequently diagnosed in adults and two
conditions—namely impaired glucose tolerance and impaired
fasting glucose—are present in people who are at higher risk for
developing diabetes. In particular, central (androgen) obesity is
directly related to diabetes in genetically susceptible subjects
(Beys et al. 2007).
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Category Number of records
Full papers Abstractsa
Initial search 50 23
records excluded 23 22
records included 27 4
Additional records identified 40
Level 1 clinical evidence
(systematic review, meta analysis)a
4 0
Level 2 clinical evidence (RCT) 27 3
Level ≥3 clinical evidence 00
Economic evidence 01
For definition of levels of evidence, see Editorial Information on inside back cover or on
Core Evidence website.
aIncludes two studies on fixed-dose combination.
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review191
Current therapy options
Every year, level 1 evidence and recommendations are published
regarding the treatment of type 1 and type 2 diabetes and its
complications (e.g. ADA 2007). Diabetes management includes not
only blood glucose control, but also treatment of complications and
comorbidity control. Diet and physical exercise are fundamental to
achieve the goals recommended for glycemic control [glycosylated
hemoglobin (HbA1c) <7%] and reducing low-density lipoprotein
cholesterol (LDL-C) (≤70 mg/dL) (Mann 2002; ADA 2007). Blood
pressure recommendations are more restrictive in diabetic patients
compared with the healthy population: systolic (SBP) and diastolic
(DBP) values of ≤130 mmHg and 80 mmHg are suggested in type 2
diabetes. Dyslipidemia is usually recommended to be treated by
statins and fibrates (MRC/BHF 1999), and aspirin treatment should
always be started in diabetic patients who present with secondary
cardiovascular risk factors, such as hypertension (UKPDS 1998;
ADA 2007).
Two major classes of drug are currently used for the treatment of
diabetes: insulin sensitizers and secretagogs. The first class
includes biguanides (primarily metformin) and TZDs (including
pioglitazone and rosiglitazone); the second comprises sulfonylureas
(SUs) (Kyvik et al. 1995), glinides (Standl & Fuchtenbusch 2003), and
alfa-glucosidase inhibitors such as acarbose and voglibose
(Ahmann & Riddle 2002). Insulin is recommended in type 2 diabetes
in nonresponding patients previously treated with oral antidiabetic
drugs or in particular situations where diabetes is poorly controlled
(e.g. surgery, intercurrent disease, pregnancy, renal impairment)
(ADA 2007). Pharmacologic treatment is started when diet and
exercise are not sufficient to achieve the therapeutic goal HbA1c
reduction to <7%. Currently, the first choice in obese [body mass
index (BMI) >30 kg/m2] type 2 diabetic patients not controlled with
diet and physical activity is metformin, an insulin sensitizer that acts
primarily in the liver, thus reducing gluconeogenesis (Takiya &
Chawla 2002). When glycemic control is not achieved with a single
drug, combination therapy is recommended (Nathan et al. 2006).
The most commonly employed combination in clinical practice, and
also the best studied, is metformin and a SU (Krentz & Bailey 2005).
SUs are secretagogs and effectively improve insulin secretion from
beta cells of pancreatic islets. The choice of SU is dependent on the
presence of a residual insulin secretion. SUs are commonly well
tolerated, although some important side effects such as weight gain
can occur during treatment (Kyvik et al. 1995). To date, SUs,
metformin, and TZDs have been shown to be similarly effective in
achieving the recommended goals for glycemic control (Bolen et al.
2007). New drugs are under development and are represented by
peptides, amino acids, and peptidomimetics (Jain & Chawrai 2005).
Recently, both pioglitazone and rosiglitazone have been approved in
the US and EU in association with insulin, and the combination of a
TZD and metformin has been introduced.
Clinical evidence with fixed-dose pioglitazone/
metformin
Bioequivalence between the fixed-dose tablets and pioglitazone
and metformin given separately has been established in terms of
absorption and bioavailability parameters in two studies in which
healthy volunteers were treated with a fixed-dose combination of
pioglitazone and metformin at two dose strengths, 15 mg/500 mg
and 15 mg/850 mg, or with the coadministration of each drug
separately (Karim et al. 2007a,b). Moreover, food had no effect on
the bioavailability of the fixed-dose combination compared with
the separate drugs.
Glycemic control
To date, the efficacy of the combined treatment with pioglitazone
and metformin may be assumed from the results of combination
clinical trials, since there are no data on glycemic control provided
by a fixed-dose combination in clinical trials (Seufert 2006).
Several randomized placebo-controlled or active comparator
trials have evaluated the efficacy of treatment with pioglitazone
and metformin on glycemic control. In a 16-week trial,
combination therapy with pioglitazone and metformin significantly
improved HbA1c (difference in mean change between groups
–0.83%; P≤0.05) and fasting plasma glucose (FPG; difference in
mean change between groups –37.7mg/dL; P≤0.05) in diabetic
patients inadequately controlled with metformin (Einhorn et al.
2000). A significant difference from baseline was observed at
week 4 for both parameters. The positive effect of pioglitazone
was sustained during the 72-week open-label extension phase of
this study. Patients treated with pioglitazone plus metformin in the
open-label phase had mean changes from baseline of –1.36% in
HbA1c and –63.0 mg/dL in FPG. The placebo plus metformin
group showed a small mean increase in fasting C-peptide from
baseline (+0.1 ng/mL) while in the pioglitazone plus metformin
group a small decrease was registered (–0.1 ng/mL), the
difference becoming significant at week 16 (P≤0.05) (Einhorn et
al. 2000).
Mounting evidence shows that pioglitazone in association with
metformin improves glycemic control to a similar extent as the
combination of rosiglitazone and metformin. In a 12-month
randomized clinical trial that directly compared the combination
of pioglitazone and metformin with rosiglitazone and metformin,
pioglitazone combined with metformin induced a significant
improvement in glycemic control (P<0.05) after 9 months of
treatment, although there was no significant difference between
groups at the end of the study. Reduction in FPG and
postprandial blood glucose were also similar between groups
(P<0.05). Another primary endpoint of this comparator study was
the effect of the two combinations on lipid profile, which is
discussed below (Derosa et al. 2007a).
The efficacy of pioglitazone and metformin combination treatment
has been compared with that of gliclazide and glibenclamide. In
comparison with gliclazide added to metformin, pioglitazone add-
on therapy induced a similar reduction of HbA1c (–0.99% vs
–1.01%), while improvement of FPG was significantly greater in
patients receiving pioglitazone plus metformin (–2.1 vs
+1.6 mmol/L)(P<0.001) (Charbonell et al. 2005). Improved
glycemic control was effectively sustained by pioglitazone and
metformin for the 52-week extension of this study, with a
statistically significant difference between groups in a
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≥18 months (–1.07% vs –0.76%) (Matthews et al. 2005). In a
26-week study, no statistically significant differences were found
between pioglitazone plus metformin and pioglitazone plus
glimepiride with regard to both FPG and HbA1c (–1.23% and
–1.30%, respectively) (Umpierrez et al 2006).
Concerning studies comparing pioglitazone in association with
either metformin or glibenclamide, both combinations were
equally effective in terms of reduction of HbA1c in two long-term
prospective trials. In a 3-year study, reduction in HbA1c at
72 weeks was greater in the pioglitazone and metformin group
(P<0.001); at 156 weeks, changes in HbA1c were –2.3% and
+1.8%, respectively, with pioglitazone plus metformin and plus
glibenclamide (Spanheimer et al. 2006). At the end of a second
study, which lasted for 96 weeks, the reduction in HbA1c was
significantly greater in the pioglitazone plus metformin group
(–0.85% vs –0.61%; P=0.025) (Oerter et al. 2006). In one
observational study, significantly fewer patients required a shift to
insulin treatment if they received pioglitazone plus metformin
(P<0.001) (Deeks & Scott 2006; Mirkolf et al. 2006).
As regards insulin sensitivity, one study was considered in our
evaluation of the literature. Pioglitazone plus metformin has been
evaluated in a clinical trial in which the primary outcome was the
comparison with gliclazide and metformin on afterload glycemia
and a composite index of insulin sensitivity (CISI) (Ceriello et al.
2005). Results of this study show that treatment with pioglitazone
plus metformin reduced fasting insulinemia while it was increased
by the combination of pioglitazone and gliclazide. HbA1c was
lowered by 1% and FPG was reduced by 1.53 mmol/L to
1.29 mmol/L without significant differences between groups
(Ceriello et al. 2005).
Cardiovascular events
Recently, a large clinical trial, PROactive, demonstrated the
efficacy of pioglitazone in reducing cardiovascular events
(Dormandy et al. 2005). The study showed that treatment with
pioglitazone is effective in improving a series of cardiovascular
risk factors, thus resulting in a general reduction of cardiovascular
morbidity and mortality; tolerability of pioglitazone at different
dosages (from 15 mg/day to 45 mg/day) was also evaluated. All
patients enrolled presented with macrovascular disease such as
recent (<6 months) acute myocardial infarction (AMI), acute
coronary syndrome, revascularization, stroke, or severe peripheral
arterial disease. The composite primary endpoint was the time
required for the presentation of a second cardiovascular event
after randomization: death from all causes, nonfatal myocardial
infarction (including silent AMI), stroke, acute coronary syndrome,
coronary or peripheral revascularization, and amputation.
Secondary endpoints were the time preceding the first all-cause
death, AMI (excluding silent AMI), and stroke (main secondary
endpoint). The primary endpoint was reduced by 10% by
pioglitazone titrated from 15 to 45 mg [pioglitazone 514/2605
events vs placebo 572/2633; hazard ratio (HR) 0.90; 95% CI: 0.80,
1.02; P=0.095]. When the primary endpoint includes only clinical
objectives, the reduction was significant in the pioglitazone group
versus placebo (16%; P=0.027). Inclusion of revascularization
events in the primary composite endpoint reduces the
significance of the results, since revascularization depends on
the likelihood of different study centres to perform this
surgical intervention.
PROactive thus demonstrated a reduction of AMI, stroke, acute
coronary syndrome, and cardiac revascularization in patients
treated with pioglitazone compared with placebo. Treatment
with pioglitazone showed a good tolerability profile in a large
number of patients. The more frequently reported adverse
events were infectious respiratory disease, headache, and
muscle pain.
Level 2 evidence has shown the clinical efficacy of metformin in
reducing cardiovascular events in overweight patients with type 2
diabetes. Patients treated with metformin had a risk reduction of
32% for any endpoint related to diabetes, 42% for diabetes-
related death (P=0.017), and 36% for all mortality (P=0.011).
Moreover, metformin did not induce weight gain and
hypoglycemia (UKPDS 1998).
Reduced cardiovascular risk
Level 2 evidence has shown that combination therapy with
pioglitazone and metformin is effective in reducing a number of
cardiovascular risk factors. Most of the results obtained in this
context show that the reduction of some conventional (Reaven
1988) and nonconventional cardiovascular risk factors are
independent of the achievement of recommended glycemic
control. Recent findings about the potential increase and/or
reduction of cardiovascular disease with TZDs are discussed
below. Here we analyze the data on treatment with pioglitazone
and pioglitazone plus metformin on cardiovascular risk factors.
Pioglitazone in association with metformin produced a significant
reduction of plasminogen activator inhibitor 1 (PAI-1) in patients
with type 2 diabetes and metabolic syndrome (P<0.05) (Derosa et
al. 2006a). When compared with rosiglitazone/metformin,
reduction in PAI-1 levels is similar after 1 year of combination
treatment. Metformin is known to reduce triglycerides, PAI-1,
factor VII, and C-reactive protein (CRP) (Despr￩s 2003). Few
studies are available investigating the antithrombotic effects of
pioglitazone or rosiglitazone in combination with metformin, and
no studies exist that directly compare the two different
combinations of pioglitazone/metformin and rosiglitazone/
metformin on PAI-1 reduction.
Recently, the effects of pioglitazone in association with metformin
on other important nonconventional cardiovascular risk factors
have been studied. Lipoprotein-a [Lp-(a)] levels have been shown
to be related to an increased risk of atherosclerosis. Lp-(a) levels
are augmented in diabetic patients and are involved in the
development of some typical complications of diabetes such as
retinopathy and percutaneous transluminal angioplasty restenosis
(Maca et al. 2002). Diabetic patients also often present
with increased levels of homocysteine (Hcy), or
hyperhomocysteinemia, which appears to be an independent risk
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factor for atherothrombotic events (Herrmann & Knapp 2002). In
a 12-month study, pioglitazone and metformin were compared
with rosiglitazone and metformin in order to evaluate the effects
of these combinations on reduction of Lp-(a) and Hcy in type
2 diabetic patients. At the end of the study no differences were
observed between the two combinations on metabolic
improvement and reduction in Hcy levels, while reduction in
Lp-(a) was observed only in the pioglitazone/metformin group
(Derosa et al. 2006b). When the effects of combinations of
glimepiride with pioglitazone and glimepiride with rosiglitazone
on homocysteinemia and Lp-(a) were evaluated, both
combinations improved Hcy levels, but only the pioglitazone
combination was associated with significant reduction in
Lp-(a) levels (Derosa et al. 2006c). In both studies pioglitazone
was administered at the lowest dosage (15 mg) and results on
Lp-(a) levels were obtained after 1 year. No long-term clinical
studies have evaluated the effects of pioglitazone and
metformin on prothrombotic states in a large cohort of diabetic
patients, and no data are available on the maintenance of a
more favorable coagulative profile after administration of
pioglitazone/metformin fixed-dose combination.
Hypertension
Based on level 1 evidence, hypertension is a well-recognized
high-risk condition in diabetic subjects and even more restrictive
recommendations have been published for the optimal control of
blood pressure values in diabetic patients (ADA 2007; Fuster et
al. 2006). Strong evidence suggests that TZDs positively affect
blood pressure values in diabetic patients. A recent meta
analysis of 32 clinical trials showed that both pioglitazone and
rosiglitazone reduce SBP by 4.7 mmHg and DBP by 43.8 mmHg.
Compared with placebo, TZD treatment resulted in a reduction of
3.47 mmHg and 1.84 mmHg for SBP and DBP, respectively
(Qayyum & Adomaytyte 2006). A combination of pioglitazone and
metformin is effective in reducing SBP and DBP in type 2
diabetic patients who have lost the physiologic nocturnal
reduction of both SBP and DBP (so-called “nondippers”). This
effect appears to be independent of the amelioration of
metabolic parameters (Negro et al. 2004). Similar effects have
been observed with rosiglitazone; in association with metformin,
rosiglitazone reduces both SBP and DBP and restores
physiologic decreases in blood pressure during the night in
nondipping diabetic patients (Negro et al. 2005). Twelve months’
comparison between pioglitazone or rosiglitazone in association
with metformin shows that both combinations result in significant
improvements in SBP and DBP (P<0.05) and a comparable
amelioration of metabolic parameters and proinflammatory state
(Derosa et al. 2007b). The combination of TZD and metformin is
associated with a slight but significant improvement in the long-
term blood pressure control of these patients and with an
improvement in the antiinflammatory state, both of which are
related to a similar reduction in insulin resistance (Derosa et
al. 2007b).
All these results are in agreement with the level 1 evidence that
TZDs are effective in reducing blood pressure and modifying
cardiovascular risk factors, and particularly macrovascular
complications, in association with metformin or SUs (Meriden
2004; Granberry & Fonseca 2005).
Both pioglitazone and rosiglitazone have been shown to
improve microalbuminuria. The results obtained in randomized
controlled trials show that the beneficial effects of TZDs on
microalbuminuria are independent of the improvement in
metabolic parameters. Compared to metformin, pioglitazone
has been shown to reduce microalbuminuria in diabetic
patients, alone or in combination with a SU. In a large clinical
trial (QUARTET) the main outcome in diabetic patients treated
with pioglitazone in association with a SU versus metformin
combination with a SU was the reduction of HbA1c by 1.2% for
both treatments; a secondary endpoint was the reduction in
microalbuminuria after combination treatment. Pioglitazone plus
a SU resulted in a significant reduction in albumin/creatinine
excretion rate (-15%) compared with metformin, which induced
a worsening (Hanefeld et al. 2004; Schernthaner et al. 2004).
TZDs, compared with other antidiabetic drugs such as SUs and
metformin, have unique effects on microalbuminuria. Other
data show that the urinary albumin/creatinine ratio is reduced
by the pioglitazone/metformin combination compared with
gliclazide/metformin (P<0.05) (Matthews et al. 2005). Some
data reported in level 1 evidence show that the urinary
albumin/creatinine ratio was also reduced in a study of
pioglitazone add-on to metformin (-10%), compared to
gliclazide add-on with (6%; P<0.05) (Erdmann 2006).
Lipid abnormalities
A positive effect of TZDs on lipid profile and lipoprotein
subfractions has been recently observed in a number of
studies. The differential effects of rosiglitazone and pioglitazone
on lipid profile have been extensively studied (van Wijk et al.
2003), and available data suggest a substantial superiority of
pioglitazone compared with rosiglitazone in improving lipid
abnormalities. Pioglitazone and rosiglitazone have significantly
different effects on plasma lipids independent of glycemic
control or concomitant lipid-lowering or other
antihyperglycemic therapy. Compared with rosiglitazone,
pioglitazone is associated with improvements in triglycerides,
high-density lipoprotein cholesterol (HDL-C), LDL particle
concentration, and LDL particle size (Goldberg et al. 2005).
Data are available on the effect of TZDs in combination with
metformin and SUs on lipids. In a recent clinical trial,
glimepiride plus pioglitazone significantly improved lipid and
lipoprotein variables, whereas the combination of glimepiride
plus rosiglitazone appears to have no clinically significant effect
on lipid metabolism in patients with type 2 diabetes and
metabolic syndrome. Treatment with pioglitazone and
glimepiride significantly lowered total cholesterol (-11%),
LDL-C (–12%), HDL-C (15%), and apolipoprotein B (Apo-B)
(–10.6%) (P=0.05), while treatment with rosiglitazone and
glimepiride increased total cholesterol (+14.9%), LDL-C
(+16.5%), triglycerides (+17.9%), and Apo-B (+10.3%) (P<0.05)
(Derosa et al. 2004).
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compared in 127 patients with type 2 diabetes who had been
previously treated with troglitazone. After 4 months of treatment
both groups had a significant increase in BMI (P<0.01). No
significant differences were observed in lipid profiles in the group
treated with rosiglitazone, while in pioglitazone recipients a
significant improvement was obtained in total cholesterol levels
(P<0.01) after adjustment for demographic profile and treatment
with statins (Khan et al. 2002). In a long-term clinical trial the
combination of metformin and pioglitazone was more effective
than both gliclazide plus pioglitazone, and gliclazide plus
metformin in improving lipid profiles (P<0.001). An analysis of
long-term studies over 2 years revealed that the effectiveness of
combination treatment with pioglitazone and metformin was
superior to pioglitazone plus gliclazide and metformin plus
gliclazide. In particular, combination treatment with pioglitazone
and metformin induced a statistically significant reduction in
triglycerides that was sustained over time, with decreases of
16–18% at 1 year and 17–23% at 2 years (P<0.01), and an
increase in HDL levels, both sustained to the end of the study. A
small but significantly greater reduction in LDL-C was obtained in
the group treated with gliclazide and metformin versus both
pioglitazone and metformin and pioglitazone and gliclazide. Mean
fasting levels of nonesterified fatty acids were decreased more in
the pioglitazone and metformin group than in the gliclazide and
metformin group (P=0.046) (Betteridge & Verges 2005).
Data from another large clinical trial show that addition of
pioglitazone to metformin and SUs alone or in combination was
more effective than adding rosiglitazone in reducing triglycerides
levels (P<0.001) and increasing HDL levels (P<0.001). The results
were consistent among all the treatment subgroups analyzed in
the study (Peters Harmel et al. 2004). Both in monotherapy and
add-on therapy to metformin and SUs, pioglitazone has been
shown to improve LDL particle size and lead to an antiatherogenic
lipid profile compared with other add-on therapy such as
metformin and SUs (Khan et al. 2004).
No large long-term clinical trials have been found that directly
compare the effects of combining metformin and pioglitazone with
other combination therapy on lipid profile and particle size and
subclass distribution of lipoproteins. Nevertheless, in a direct
comparison between pioglitazone plus metformin and
rosiglitazone plus metformin, a significant lipid profile improvement
was present in the pioglitazone group at 12 months compared with
the baseline values, and these variations were significantly
different between groups (Derosa et al. 2006b). Pioglitazone and
metformin combination treatment has also shown positive effects
on LDL subfractions (Lawrence et al. 2004). Pioglitazone and
metformin combination treatment reduced LDL particle size and
apolipoprotein levels [Apo-AI, Apo-AI/AII-containing HDL, and
Lp-(a)] and increased Apo-B (Perez et al. 2004).
Increasing evidence indicates an endocrine role of adipose tissue,
producing a series of endocrinologically active molecules,
adipocytokines. Diabetic patients usually have low levels of
adiponectin, which is inversely related to insulin sensitivity. In a
12-week study, pioglitazone monotherapy increased adiponectin
levels in type 2 diabetic patients compared with metformin, while
leptin levels (reduced in diabetic patients at baseline) appeared
unaffected by pioglitazone monotherapy and improved by
metformin (Sharma et al. 2006). Fixed-dose combination studies
are not available investigating lipid effects.
Safety and tolerability
According to level 2 evidence, oral administration of pioglitazone
(30–45 mg) plus metformin therapy was generally well tolerated in
long-term clinical trials (Einhorn et al. 2000; Matthews et al. 2005).
Data come primarily from descriptive analyses and are partially
derived from the manufacturer’s prescribing information
(Anon. 2007).
Combination treatment with pioglitazone and metformin presents
a tolerability profile comparable to metformin monotherapy, the
common side effects of which are principally nausea, diarrhea,
and gastrointestinal discomfort. The safety and tolerability of
pioglitazone in combination with metformin was compared with
rosiglitazone plus metformin in a 12-month study. With both
treatments no statistically significant change was detected
compared with baseline values (Derosa et al. 2006b). Clinical trials
report a low incidence of edema (peripheral and combined) and
headache (Deeks & Scott 2006). Tolerability of the two dosages of
pioglitazone (30 and 45 mg) was similar, with a small difference in
limb edema according to a 52-week clinical trial (Matthews et
al. 2005).
Cardiac events
Cardiovascular risk has recently become the key issue in TZD
therapy, and cardiovascular risk of a fixed-dose combination
cannot be analyzed without including the recent findings in the
literature. A recent meta analysis of 42 randomized control trials
involving 28 443 patients treated with rosiglitazone showed an
increase in the risk of AMI compared with controls (odds ratio
1.43; 95% CI 1.03, 1.98; P=0.03) (Nissen & Wolski 2007). A
subsequent meta analysis included randomized clinical trials with
a specified intention to evaluate cardiovascular events in diabetic
and nondiabetic populations (prediabetic). The studies included
had almost a 12-month follow-up period and provided numerical
data of cardiovascular side effects. Results of this analysis
showed that rosiglitazone increases the risk of AMI [relative risk
(RR) 1.42%; 95% CI 1.06, 1.91; P=0.02] and congestive heart
failure (RR 2.09; 95% CI 1.52, 2.88; P<0.001) without raising the
risk of cardiovascular mortality (RR 0.90; 95% CI 0.63, 1.26;
P=0.53) (Nissen et al. 2007). The limitations of collecting data
from the studies included in the analysis and the limitations of a
meta analysis in itself are analyzed in the paper. After having
considered these data, the rosiglitazone label was modified by the
Food and Drug Administration in August 2007 (Singh et al. 2007).
Data from the PROactive trial, as explained above, revealed a
favorable impact of pioglitazone on cardiovascular risk. In
particular, long-term treatment with pioglitazone seems to reduce
the risk of AMI. However, the issues raised by the meta analysis
of Nissen et al. (2007) have made it necessary to better
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understand the potential of an increase in AMI in patients treated
with pioglitazone. In another recent meta analysis, the effect of
pioglitazone on ischemic and cardiovascular events has been
investigated (Lincoff et al. 2007). The studies included (n=19) in
this analysis had to be randomized clinical trials, double-blind and
controlled with placebo or active comparator. The primary
outcome measure was a composite of death, AMI, or stroke, and
secondary endpoint measures included the incidence of serious
heart failure. Death, AMI, or stroke occurred in 4.4% of patients
receiving pioglitazone versus 5.7% patients receiving control
drugs (HR 0.82; 95% CI 0.72, 0.94; P=0.005), with a similar
magnitude in reduction of each individual component of the
primary endpoint (HR range 0.80–0.92), while serious heart failure
was registered in 2.3% of the patients treated with pioglitazone
versus 1.8% of patients receiving control drug therapy (HR 1.41;
95% CI 1.14, 1.76; P=0.002).
In summary, the evidence indicates that pioglitazone is
associated with a reduced risk of death, AMI, or stroke among
a diverse population of patients with type 2 diabetes. The drug
was associated with an increased risk of heart failure, but
without an increase in resultant mortality.
Edema
Edema represents one of the most common and undesirable
side effects of treatment with a TZD, and appears to be more
common when TZDs are used in combination therapy. In the
study by Matthews et al. (2005), the incidence of edema
in patients treated with pioglitazone and metformin was
6.3%, compared with 2.2% in patients treated with
gliclazide and metformin. One patient discontinued treatment
because of edema, while pulmonary edema developed in two
patients, which was considered to be related to drug therapy in
one patient and was accompanied by AMI (Matthews et al.
2005). A number of studies report an increased risk of edema in
patients treated with pioglitazone, and in combination studies
(not fixed-dose studies) this event has also been reported.
In the study by Einhorn et al. (2000) peripheral edema and
central edema occurred in 5.9% of the pioglitazone plus
metformin group, but it was described as mild to moderate. No
studies with the fixed-dose combination of pioglitazone/
metformin are available that directly evaluate the increase of
edema with this formulation.
Fluid retention with TZDs has been associated with different
mechanisms and may be considered a multifactorial process.
Level 1 evidence is available regarding these different
mechanisms, and it may also be considered in the context of
recent controversies about heart failure with TZDs (see Place in
therapy). The evidence indicates that pioglitazone and
rosiglitazone induce edema more in combination therapy than
as monotherapy, and in particular when administered with
insulin or SUs (Nesto et al. 2004). Excluding insulin combination
therapy, there is no apparent difference between the different
combinations with pioglitazone or rosiglitazone and no head-
to-head comparisons have been performed or reported to
investigate this effect.
Aminotransferase increase
Increase of alanine aminotransferase (ALT) levels (≥3 times the
upper level) was limited in clinical trials (Anon. 2007). In a 3-year
randomized double-blind safety study (Spanheimer et al. 2006)
the incidence of ALT elevation ≥3 times the upper limit during
treatment with pioglitazone and metformin was comparable to
that with glibenclamide and metformin. In the same study, the
incidence of ALT and gamma-glutamyl-transpeptidase >1.5 the
upper limit and/or baseline was significantly more frequent with
glibenclamide than with pioglitazone/metformin. Aspartate
aminotransferase (AST) elevation was more frequent with
pioglitazone but the mean change of AST and ALT concentrations
were lower in the pioglitazone group (Spanheimer et al. 2006).
Hypoglycemia
As reported in clinical trials, hypoglycemia was less frequent with
pioglitazone in association with metformin than with the
combination of SUs and metformin. These data have been
confirmed in short- and long-term clinical trials that have
compared pioglitazone in association metformin with the different
SUs glimepiride (Umpierrez et al. 2006), gliclazide (Charbonell et
al. 2005), and glibenclamide (Perez et al. 2006) when given
with metformin.
Lactic acidosis
Lactic acidosis occurs primarily in patients treated with
metformin, particularly those with renal impairment, hypoxia,
heart failure, and other risk factors for acidosis. According to
data from clinical trials there were no reported cases of lactic
acidosis in more than 20 000 patient-years with pioglitazone and
metformin combination treatment (Anon. 2007). The reported
incidence of lactic acidosis in patients receiving metformin is very
low (0.03 cases/1000 patient-years). Reported cases occurred in
patients with renal insufficiency, advanced age, heart failure,
excessive alcohol intake, intravascular radiocontrast injection,
and respiratory disease. No evidence exists regarding the risk of
lactic acidosis with pioglitazone or fixed-dose pioglitazone and
metformin add-on therapy (Anon. 2007).
Increase in bodyweight
A moderate bodyweight gain is well known in patients treated
with TZDs, due to the stimulation of preadipocyte differentiation.
In a 12-month comparative study between pioglitazone and
rosiglitazone associated with metformin, no BMI changes were
observed in either group (Derosa et al. 2007a). Combination with
pioglitazone gives rise to a small increase in bodyweight when
compared with metformin alone, which slightly decreases
bodyweight (+0.95 kg vs –1.36 kg after 16 weeks) (Einhorn et al.
2000). In other studies, combination treatment of pioglitazone and
metformin was associated with weight gain, to a similar degree to
that observed with metformin and gliclazide (+1.5 kg vs +1.4 kg
compared with gliclazide alone after 52 weeks) (Matthews et al.
2005) and glimepiride (+1.74 kg vs +1.85 kg after 28 weeks)
(Umpierrez et al. 2006).
Pioglitazone/metformin | Place in therapy review
Core Evidence 2007;2(3)Economic evidence
No economic studies are available for the fixed-dose pioglitazone
and metformin formulation; a health technology assessment on
pioglitazone and rosiglitazone pubished in 2004 also reported no
published economic studies on either drug (Czoski-Murray et al.
2004). Direct head-to-head comparisons of the glitazones in
combination with metformin or SUs would be helpful.
Dosage, administration, and formulations
Fixed-dose tablets of pioglitazone/metformin are approved in the
US (15 mg/500 mg and 15 mg/850 mg) and EU (15 mg/850 mg) for
the treatment of patients with type 2 diabetes who fail to achieve
glycemic control with monotherapy, and monotherapy with
metformin, respectively. In the US, in inadequately controlled
glycemia with pioglitazone or metformin alone, and in patients
currently receiving pioglitazone plus metformin, the recommended
dosage of the pioglitazone/metformin combination is 15 mg/500 mg
or 15 mg/850 mg once or twice daily. The maximum recommended
dosage is 45 mg/2550 mg per day. In the EU, 15 mg/850 mg twice
daily is the recommended dosage in patients in whom glycemia is
inadequately controlled with metformin alone.
Place in therapy
As discussed in this review, pioglitazone and metformin
coadministration improves glycemic control, insulin sensitivity, and
lipid profiles, which remain the cardinal points of diabetes care.
The different mechanism of action of two insulin-sensitizing agents
leads to the optimized control of the different pathways that lead
to insulin resistance, inflammation, and atherosclerosis. Despite
the lack of long-term clinical trials of the fixed-dose combination of
pioglitazone and metformin in the management of cardiovascular
risk factors, the evidence of a possible effect of pioglitazone on
proinflammatory markers, adipocytokines, and procoagulative
state supports its use in the treatment of metabolic syndrome. On
the other hand, recent data from meta analyses of rosiglitazone
and pioglitazone have to be considered before discussing the
possible role of a fixed-dose combination of pioglitazone and
metformin in prevention of cardiovascular risk. The major limits
observed in meta analyses of rosiglitazone and pioglitazone are
the unfortunate lack of studies intended to assess cardiovascular
outcomes in patients treated with TZDs (Lincoff et al. 2007; Singh
et al. 2007). No studies are available where the primary outcome is
cardiovascular mortality with the fixed association of metformin
plus a TZD. Large clinical trials investigating cardiovascular
outcomes in patients treated with pioglitazone monotherapy are
required, as are studies on the comparison between pioglitazone
with other older drugs such as metformin and SUs. A retrospective
analysis conducted in patients treated with antidiabetic drugs
other than TZDs (metformin, SUs, or insulin) as monotherapy or
combination therapy demonstrated that the incidence of heart
failure among patients with type 2 diabetes is more frequent with
any drug therapy, with little difference between treatments. The
risk of AMI seems to be slightly higher during the first year, with
risk of heart failure decreasing thereafter to become comparable to
that in patients treated with diet and physical activity. Regarding
pioglitazone either alone or in combination with metformin, no
studies are available that can explain such a relationship.
In this brief discussion many unsolved questions emerge relating
to the real risk (rosiglitazone) and/or benefit (pioglitazone) TZDs
could bring in the prevention of cardiovascular events. For
example, how many studies are reliable enough to make
conclusions about cardiovascular outcomes? And are the studies
comparable? There is a lack of evidence in this regard on newer
formulations such as pioglitazone plus metformin and rosiglitazone
plus metformin in fixed-dose combinations, but there is evidence
that these combinations improve glycemic control in type 2
diabetes. There are two issues that need to be considered: the
direct and/or indirect mechanisms that link hyperglycemia itself
and insulin resistance with coronary damage and atherosclerosis
development are still partially unknown, and the interaction
between pioglitazone and metformin with the pathophysiological
steps that lead to atherosclerosis in some metabolic diseases
such as diabetes.
Despite these issues, our opinion is that glycemic control remains
the objective of treatment, and strong evidence exists for the
beneficial effect of a fixed-dose combination. Obesity may be
managed as one of the major steps to early atherosclerosis and
the assessment of fat tissue should be one of the outcomes
for clinicians.
Diabetic patients are often treated with multiple drugs, and may
require a more practical and convenient therapeutic regimen,
which can be provided by a fixed-dose combination. Side effects
do not appear to be increased when a fixed dose is compared with
monotherapy or other combination therapy, when drugs are
administered according to manufacturers’ advice. More studies
are needed on the potential economic impact of fixed-dose
combination treatment with pioglitazone and metformin, and
large-scale, long-term clinical trials will provide clear evidence of
the potential preventive effects on macro- and microvascular
complications of type 2 diabetes.
Acknowledgments
The authors declare that they have no conflict of interest.
References
ADA (American Diabetes Association). Standards of medical care in diabetes –
2007. Diabetes Care. 2007;30(Suppl. 1):S4–S41.
Ahmann AJ, Riddle MC. Current oral agents for type 2 diabetes. Many options
but which to choose when? Postgrad Med. 2002;111:32–46.
Anon. Actoplus prescribing information. Deerfield, IL: Takeda Pharmaceuticals
America, Inc.; 2007. Available at:
http://www.actos.com/actos/prescribinginfo.aspx (accessed August 2007).
Betteridge DJ, Verges B. Long-term effects on lipids and lipoproteins of
pioglitazone versus gliclazide addition to metformin and pioglitazone versus
metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Diabetologia. 2005;48:2477–2481.
Bays HE, Bazata DD, Clark NG, et al. Prevalence of self-reported diagnosis of
diabetes mellitus and associated risk factors in a national survey in the US
population: SHIELD (Study to Help Improve Early evaluation and management
of risk factors Leading to Diabetes). BMC Public Health. 2007;7:277–303.
Pioglitazone/metformin | Place in therapy review
ﾩ 2007 Core Medical Publishing Limited 196197
Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative
effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann
Intern Med. 2007;147:386–399.
Ceriello A, Johns D, Widel M, et al. Comparison of the effect of pioglitazone
with metformin or sulphonylurea (monotherapy and combination therapy) on
post-load glycemia and composite insulin sensitivity index during an oral
glucose tolerance test in patients with type 2 diabetes. Diabetes Care.
2005;28:266–272.
Charbonell BH, Schernthaner G, Brunetti P, et al. Long-term efficacy and
tolerability of add-on pioglitazone therapy to failing monotherapy compared
with addition of gliclazide or metformin in patients with type 2 diabetes.
Diabetologia. 2005;48:1093–1104.
Czoski-Murray C, Warren E, Chilcott J, et al. Clinical effectiveness and cost-
effectiveness of pioglitazone and rosiglitazone in the treatment of type 2
diabetes: a systematic review and economic evaluation. Health Technol Assess.
2004;8:iii,ix–x, 1–91.
Deeks ED, Scott LJ. Pioglitazone/metformin. Drugs. 2006;66:1863–1877.
Derosa G, Cicero AF, Gaddi A, et al. Metabolic effects of pioglitazone and
rosiglitazone in patients with diabetes and metabolic syndrome treated with
glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled,
parallel-group trial. Clin Ther. 2004;26:744–754.
Derosa G, D’Angelo A, Ragonesi PD, et al. Effects of rosiglitazone and
pioglitazone combined with metformin on the prothrombotic state of patients
with type 2 diabetes mellitus and metabolic syndrome. J Int Med Res.
2006a;34:545–555.
Derosa G, D’Angelo A, Ragonesi PD, et al. Metformin-pioglitazone and
metformin-rosiglitazone effects on non-conventional cardiovascular risk factors
plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm
Ther. 2006b;31:375–383.
Derosa G, Cicero AFG, D’Angelo A, et al. Effects of 1 year of treatment with
pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and
homocysteine concentrations in patients with type 2 diabetes mellitus and
metabolic syndrome: a multicenter, randomized, double-blind, controlled
clinical trial. Clin Ther. 2006c;28:679–688. (erratum: Clin Ther. 2006;28:1483.)
Derosa G, D’Angelo A, Ragonesi PD, et al. Metabolic effects of pioglitazone
and rosiglitazone in patients with diabetes and metabolic syndrome treated
with metformin. Int Med J. 2007a;37:79–86.
Derosa G, Fogari E, Cicero AF, et al. Blood pressure control and inflammatory
markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone
and metformin. Hypertens Res. 2007b;30:387–394.
Despr￩s JP. Potential contribution of metformin in the management of
cardiovascular disease risk in patients with abdominal obesity, the metabolic
syndrome and type 2 diabetes. Diabetes Metab. 2003;29:6S53–6S61.
Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of
macrovascular events in patients with type 2 diabetes in the PROactive Study
(PROspective pioglitAzone Clinical Trial In macroVascular Events): a
randomised controlled trial. Lancet. 2005;366:1279–1286.
Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in
combination with metformin in the treatment of type 2 diabetes mellitus: a
randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin
Ther. 2000;22:1395–1409.
Erdmann E. Microalbuminuria as a marker of cardiovascular risk in patients with
type 2 diabetes. Int J Cardiol. 2006;107:147–153.
Gilmer TP, Roze S, Valentine WJ, et al. Cost-effectiveness of diabetes case
management for low-income populations. Health Serv Res.
2007;42:1943–1959.
Goldberg RB, Kendall DM, Deeg MA, et al. GLAI Study Investigators. A
comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in
patients with type 2 diabetes and dyslipidaemia. Diabetes Care.
2005;28:1547–1554.
Granberry MC, Fonseca VA. Cardiovascular risk factors associated with insulin
resistance: effects of oral antidiabetic agents. Am J Cardiovasc Drugs.
2005;5:201–209.
Haffner SM. Abdominal adiposity and cardiometabolic risk: do we have all the
answers?. Am J Med. 2007;120(Suppl. 1):s10–s16.
Hanefeld N, Brunetti P, Schernthaner GH, et al. One-year glycemic control with
a sulphonylurea plus piolgitazone versus a sulphonylurea plus metformin in
patients with type 2 diabetes. Diabetes Care. 2004;27:141–147.
Herrmann W, Knapp JP. Hyperhomocysteinemia: a new risk factor for
degenerative disease. Clin Lab. 2002;48:471–481.
IDF (International Diabetes Federation). Diabetes Atlas. 3rd ed. Brussels:
International Diabetes Federation; 2006. Available at http://www.eatlas.idf.org
(accessed December 5, 2007).
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and the risk of
cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis
of randomized trials. JAMA. 2007;298:1180–1188.
Jain R, Chawrai S. Advancements in the anti-diabetes chemotherapeutic based
on amino acids, peptids and peptidomimetics. Mini Rev Med Chem.
2005;5:469–477.
Karim A, Slater M, Bradford D, Schwartz L, Laurent A. Oral antidiabetic drugs:
effect of food on absorption of pioglitazone and metformin from a fixed-dose
combination tablet. J Clin Pharmacol. 2007a;47:48–55.
Karim A, Slater M, Bradford D, et al. Oral antidiabetic drugs: bioavailability
assessment of fixed-dose combination tablets of pioglitazone and metformin.
Effect on body weight, gender and race on systemic exposures of each drug.
J Clin Pharmacol. 2007b;47:37–47.
Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the
metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes
who were previously treated with troglitazone. Diabetes Care. 2002;25:708–711.
Khan M, Xu Y, Edwards G, et al. Effects of pioglitazone on the components of
diabetic dyslipidemia: results of double-blind multicenter randomised studies.
Int J Clin Pract. 2004;58:907–912.
Krentz AJ, Bailey CJ. Oral antidiabetic agents. Drugs. 2005;65:385–411.
Kyvik KO, Green A, Beck-Nielsen H. Concordance rates of insulin dependent
diabetes mellitus : a population race study of young Danish twins. BMJ.
1995;311:913–917.
Lawrence JM, Reid J, Taylor GJ, et al. Favorable effects of pioglitazone and
metformin compared with gliclazide on lipoprotein subfractions in overweight
patients with early type 2 diabetes. Diabetes Care. 2004;27:41–46.
Maca TH, Ahmadi R, Dergfler K, et al. Influence of lipoprotein (a) on restenosis
after femoro-popliteal percutaneous transluminal angioplasty in type 2 diabetic
patients. Diab Med. 2002;19:300–306.
Mann JI. Diet and risk of coronary heart disease and type 2 diabetes. Lancet.
2002;360:783–789.
Matthews DR, Charbonnel BH, Hanefeld M, et al. Long-term therapy with
addition of pioglitazone to metformin compared with the addition of gliclazide to
metformin in patients with type 2 diabetes: a randomized, comparative study.
Diabetes Metab Res Rev. 2005;21:167–174.
Meriden T. Progress with thiazolidinediones in the management of type 2
diabetes mellitus. Clin Ther. 2004;26:177–190.
Mirkolf H, Luebben G, Pfuetzner A, et al. Pioglitazone vs glibenclamide:
significant differences in glycemic control and treatment failure rates in patients
with type 2 diabetes mellitus. Presented at: 66th Scientific Sessions of the
American Diabetes Association; June 9–13, 2006; Washington, DC.
Abstract n 604 p.
MRC/BHF (Medical Research Council/British Heart Foundation). Heart
Protection Study of cholesterol-lowering therapy and of antioxidant vitamin
supplementation in a wide range of patients at increased risk of coronary heart
disease death: early safety and efficacy experience. Eur Heart J.
1999;20:725–741.
National Service Framework for Diabetes. Standards 2001. Available at:
www.doh.gov.uk/nsf/diabetes/ (accessed August 2007).
Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in
type 2 diabetes: A consensus algorithm for the initiation and adjustment of
therapy: a consensus statement from the American Diabetes Association and
the European Association for the Study of Diabetes. Diabetes Care.
2006;29:1963–1972.
Negro R, Dazzi D, Hassan H, et al. Pioglitazone reduces blood pressure in non-
dipping diabetic patients. Minerva Endocrinol. 2004;29:11–17.
Pioglitazone/metformin | Place in therapy review
Core Evidence 2007;2(3)Negro R, Mangieri T, Dazzi D, et al. Rosiglitazone effect on blood pressure and
metabolic parameters in nondipper diabetic patients. Diabetes Res Clin Pract.
2005;70:20–25.
Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention and
congestive heart failure. A consensus statement from the American Heart
association and American Diabetes Association. Diabetes Care.
2004;27:256–263.
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction
and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471.
Oerter E, Lippmann-Grob, Luebben G. Pioglitazone vs glibenclamide: focus on
metabolic control and health economic impact. Presented at: 66th Scientific
Sessions of the American Diabetes Association; June 9–13, 2006; Washington,
DC. Abstract 539-P.
Perez A, Khan M, Johnson T, et al. Pioglitazone plus a sulphonylurea or
metformin is associated with increased lipoprotein particle size in patients with
type 2 diabetes. Diab Vasc Dis Res. 2004;1:44–50.
Perez A, Spanheimer R, Kupfer S, et al. Cardiovascular safety profile of
pioglitazone vs glyburide: results from a 3-year randomized, double blind trial.
Presented at: 66th Scientific Sessions of the American Diabetes Association;
June 9–13, 2006; Washington, DC. Abstract 1994-PO.
Peters Harmel AL, Kendall DM, Buse JB, et al. Impact of adjunctive
thiazolidinedione therapy on blood lipid levels and glycemic control in patients
with type 2 diabetes. Curr Med Res Opin. 2004;20:215–223.
Qayyum R, Adomaytyte J. A meta-analysis of the effects of thiazolidinediones
on blood pressure. J Clin Hypertens. 2006;8:19–28.
Reaven G. Role of insulin resistance in human disease. Diabetes.
1988;37:1595–1607.
Rosak C. The pathophysiologic basis of efficacy and clinical experience with
the new oral antidiabetic agents. J Diabetes Complications. 2002;16:123–132.
Schernthaner G, Matthews DR, Charbonnel B, et al. Efficacy and safety of
pioglitazone versus metformin in patients with type 2 diabetes mellitus: a
double-blind, randomized trial. J Clin Endocrinol Metab. 2004;89:6068–6076.
Seufert J. A fixed-dose combination of pioglitazone and metformin: a promising
alternative in metabolic control. Curr Med Res Opin. 2006;22(Suppl. 2):s39–s48.
Sharma PK, Bhansali A, Sialy R, et al. Effects of pioglitazone and metformin on
plasma adiponectin in newly detected type 2 diabetes mellitus. Clin Endocrinol.
2006;65:722–728.
Singh S, Loke YK, Furberg CD. Long term risk of cardiovascular events with
rosiglitazone. A meta-analysis. JAMA. 2007;298:1189–1195.
Spanheimer R, Perez A, Kupfer S, et al. The effects of pioglitazone vs glyburide
on glycemic control in patients with type 2 diabetes in a 3-year randomized
double-blind trial. Presented at: 66th Scientific Sessions of the American
Diabetes Association; June 9–13, 2006; Washington, DC. Abstract 320-OR
Standl E, Fuchtenbusch M. The role of oral antidiabetic agents: why and when
to use an early phase insulin secretion agent in type 2 diabetes mellitus.
Diabetologia. 2003;46(Suppl. 1):M30–M36.
Takiya L, Chawla S. Therapeutic options for the management of type 2 diabetes
mellitus. Am J Manag Care. 2002;8:1009–1023.
Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination
therapy in subjects with type diabetes inadequately controlled on metformin
monotherapy: results of a randomized clinical trial. Curr Med Res Opin.
2006;22:751–759.
UKPDS (UK Prospective Diabetes Group). Effect of intensive blood glucose
control with metformin on complications in overweight patients with type 2
diabetes (UKPDS 34). Lancet. 1998;352:854–865.
van Wijk JP, de Koning EJ, Martens EP, et al. Thiazolidinedones and blood
lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2003;23:1744–1749.
White JR, Davis SN, Cooppan R, et al. Clarifying the role of insulin in type 2
diabetes management. Clin Diabetes. 2003;21:14–21.
Correspondence: Prof Giuseppe Derosa, Department of Internal
Medicine and Therapeutics, University of Pavia, Fondazione
IRCCS Policlinico San Matteo, P. le Golgi 19, 27100 Pavia, Italy or
at giuseppe.derosa@unipv.it
Pioglitazone/metformin | Place in therapy review
ﾩ 2007 Core Medical Publishing Limited 198